78 results about "Immunological tests" patented technology

The invention belongs to the technical field of biomolecular labeling, in particular to a method for preparing an amino functional magnetic fluorescent coding microsphere with double-nucleocapsid structure. Two semiconductor quantum dots with different fluorescence colors and superparamagnetic ferric oxide nano-particles are embedded in a same silicon dioxide nano-particle in inverse microemulsion to form an amino functional magnetic fluorescent coding microsphere which has the granularity between 40nm and 100nm, high fluorescence intensity and high stability. The invention adjusts the fluorescence position and the intensity of the microsphere by changing the sort and the proportion of the quantum dots of different fluorescence colors and realizes different fluorescent coding. The addition of superparamagnetic ferroferric oxide ensures that the microsphere can gather and move fast in a targeted way under the action of an externally-applied magnetic field. Through amido modification on the surface of the microsphere, the invention can be widely applied to the fields of immunological test, nucleic acid hybridization, gene analysis, cell classification and imaging, etc.

The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g., an enzyme, fluorescent or direct label, etc.) wherein the conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e., which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte.

The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. One of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 38 to 50. In addition, one of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 1 to 37 or 43 to 76. The epitope recognized by the antibodies can slightly overlap.

The invention concerns a method for increasing the dynamic measuring range of especially immunological test elements in particular immunological chromatography test strips that can be evaluated optically that are based on specific binding reactions. The invention enables the dynamic measuring range of test elements based on specific binding reagents, especially of immunological test elements to be shifted towards higher analyte concentrations without impairing the lower detection limit. For this purpose it is proposed according to the invention that at least two zones are provided in or on the test element which contain reagents that generate detectable signals of different strengths due to different affinities for the analyte (for example in the case of antibodies that have different affinities for the analyte) or due to different principles of interaction with the analyte or with other reagents involved in the analyte detection (for example antibodies directed against the analyte in one zone and an analyte analogue in another zone). The signals in the at least two zones are used to evaluate the analyte concentration-signal strength relationship and are used to determine the analyte by means of a suitable method (correlation).

The present invention relates to an immunological test kit and immunoassay using a first immobilized antibody having affinity for a specific antigen. The invention is characterized by a second and third antibody being specific for different determinants of the antigen and modified with cross-linkable oligonucleotides. For detection, the oligonucleotides are amplified, whereby only such oligonucleotides will be amplified which have been cross-linked to each other. In this way unspecific background is avoided and detection is possible down to single molecules.

The invention provides a truncated-form streptococcus hemolyticus bacteriolysin O gene and an ASO detection kit. According to the invention, part of SLO gene fragments are cloned, and the part of SLO genes are cloned into an expression vector of escherichia coli and the like so as to realize mass expression and facilitate purification. In particular, the invention provides a DNA sequence which has a base sequence as shown in SEQ ID NO:1. According to the invention, the truncated-form SLO sequence can greatly improve the yield of SLO protein; more than 150 mg of SLO protein can be obtained through purification of one liter of bacterial culture, and the purity is more than 90%; immunological tests prove that the sectionally expressed SLO still maintains the specific immunogenicity.

The invention relates to an application of a flavonoid compound, the flavonoid compound is 3, 3', 4', 5, 7-pentahydroxyflavone dihydrate, the ELISA and protein fluorescence quenching experiments provethat the compound can effectively inhibit interaction of PD-1/PD-L1 proteins, and has a strong affinity for PD-L1 protein. Cell clone number formation and ELISA detection of IL-2 secretion assay prove that the compound can effectively enhance the tumor killing activity of T lymphocyte Jurkat cells against MDA-MB-231 and NCI-H460 tumor cells as well as the expression level of IL-2, and then reverse T cellular immunosuppression. The research results of the application provide a drug for tumor immunotherapy targeting the PD-1/PD-L1 immunological test site.

The invention relates to a rabbit hemorrhagic disease virus(RHDV) colloidal gold test strip, and belongs to the technical field of immune tests of the colloidal gold. One end of a bottom plate of the test strip is a colloidal gold-RHDV polyclonal antibody combination glass fiber film, and an antibody solid-phase cellulose nitrate film is arranged on the middle part of the bottom plate; a RHDV single-resistance test line, namely T line and a goat anti-rabbit IgG control line, namely C line are arranged on the bottom plate; and the other end of the bottom plate is absorbent paper. When a tested sample is carried with the RHDV, the RHDV can specifically combine the anti-RHDV polyclonal antibody labeled by the colloid so as to be identified by the anti-RHDV monoclonal antibody, namely the double-antibody sandwich specific combination happens, so that whether the sample is carried with the RHDV can be tested. The invention also provides a RHDV immunological test method established by utilizing the monoclonal antibody and the polyclonal antibody, which has the advantages of quickness, accuracy, convenience and the like, and the method is particularly suitable for the on-the-spot test and preliminary screening test and has bright prospect.

Sample pretreatment solutions for influenza virus tests by immunochromatography are described.

Methods detecting influenza virus by immunochromatography using the sample pretreatment solutions and Kits comprising the sample pretreatment solution and an immunochromatographic device are also described.

A plurality of individual single column test elements are provided for use in a clinical testing apparatus. Each test element is defined by a single test column that includes a quantity of a test material, such as gel material or a bead matrix, including a cover strip used to access the contents of the test column. Individual test elements can be stored, retained and dispensed for testing patient samples.

The invention belongs to the technical field of immunological test, and in particular relates to a method for preparing Sudan 1 capable of being directly marked and application of the Sudan 1. In the method, a technical route of denovo synthesis is mainly utilized, amino active group is introduced successfully on the premise of not changing an antigenic determinant in a host molecular structure of the Sudan 1, and a trim capable of directly being connected with fluorescent substances and enzymes is provided for the Sudan 1; and an important problem of competitive antigen preparation is solved for establishing a Sudan 1 competitive method enzyme-linked immuno sorbent assay (ELISA) detection system. The whole method is simple and practicable, easy to operate, and high in efficiency of connecting the fluorescent substances and the enzymes.

A process is provided for analyzing a specimen of biological material in any of a number of biochemical or immunological tests for an analyte which involves subjecting the specimen to treatment which develops a color correlating to the amount of analyte in the specimen. According to the invention at least one defined color characteristic selected from hue angle, chroma, saturation and lightness of the developed color is measured and the results of that measurement analyzed to determine the presence or concentration of the analyte in the specimen. Particular applications are to the detection of cancerous or pre-cancerous abnormalities from the analysis of lung mucus, throat mucus, cervical mucus or seminal fluid.

The invention discloses brucella abortus immune marking recombinant strain and the application thereof in preparation of vaccine. The recombinant strain is obtained by inactivating glycosyltransferase gene in the brucella abortus. The recombinant bacterial strain has weaker toxicity, can be taken as vaccine to immunize animals without inactivation, and can distinguish immune vaccinated animals from clinically diseased animals by means of a serological technology. By being immunized with the strain of the invention, a mouse generates antibody and standard bacterial strain which are different from the existing strain, so that the diseased animals can be distinguished from the immunized animals by the immunological test of animal sera. The invention is applicable to improving the brucella abortus vaccine, researching diagnosis identification agent, and developing the brucella abortus vaccine and the matched diagnosis identification agent, and has significant meaning for eradicating and cleaning the brucella abortus of the animals in the world.

The invention discloses a monoclonal antibody capable of resisting heavy metal copper. The monoclonal antibody is secreted by the hybridoma cell strain C9D11 with the CCTCC NO of C201087. The monoclonal antibody capable of resisting heavy metal copper has high potency. The antibody of the invention can be used for the immunological test of the residual copper ions. The advantages of the antibody, namely high speed, low price, sensitivity and high specificity can be utilized to develop a convenient field testing method, thus the method is suitable for the sampling test of agricultural and livestock products and the rapid test of customs clearance. The monoclonal antibody has practical significance in increasing the efficiency and quality of risk assessment and ensuring the food safety.

The invention provides a specific monoclonal antibody capable of combining a human vascular endothelial growth factor (VEGF). The monoclonal antibody has the speciality of specially combining the human VEGF. The invention also provides the application of the monoclonal antibody in the aspects of scientific research and immunological test.